 |
| November 2021 |
BCG Vaccine Not Found Protective Against COVID-19 Infection, Severity
Early in the COVID-19 pandemic, the suggestion that the bacillus Calmette-Guérin (BCG) vaccine might be protective against the novel coronavirus sparked a lot of excitement. Several ecological epidemiological studies appeared to support the hypothesis. Two new case-control studies suggest that is not the case, however, and prior vaccination against tuberculosis does not protect against infection or severity. Read more.
| | |
ACIP Recommends Shingrix for Immunocompromised Patients Aged 19 Years and Older
The Advisory Committee on Immunization Practices (ACIP) has recommended to the CDC that the recombinant zoster vaccine, marketed as Shingrix, be used for adults aged 19 years and older who are or will be immunodeficient or immunosuppressed due to disease or therapy. Find out how the recommendation will become policy, what data led to the unanimous committee vote, and how the vaccine will be administered.
|
|
|
|
|
Three-Antigen Hepatitis B Vaccine Appears Safe, Effective in Young Adults
Rates of vaccination against hepatitis B, a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, remain low in adults. In addition, current products have some limitations, including prolonged time to achieve seroprotection, with only 30% to 40% of adults seroprotected after two doses. That's why researchers compared a 3-antigen version against the current single-antigen hepatitis B vaccine.
|
|
|
Connect With U.S. Pharmacist
    |
|
|
|
|
.jpg)
